CLAIMS

1. Use of an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising a eukaryotic expression cassette encoding PD-L1 in the manufacture of a medicament for the treatment of cancer, wherein the attenuated strain of Salmonella is *Salmonella typhi Ty21a*.

2. The use according to claim 1, wherein the expression cassette comprises a CMV promoter.

3. The use according to claim 1 or 2, wherein PD-L1 is selected from the group consisting of PD-L1 having the amino acid sequence as found in SEQ ID NO 1 and a protein that shares at least 80% sequence identity therewith and PD-L1 having the amino acid sequence as found in SEQ ID NO 2 and a protein that shares at least 80% sequence identity therewith and PD-L1 having the amino acid sequence as found in SEQ ID NO 13 and a protein that shares at least 80% sequence identity therewith.

4. The use according to claim 3, wherein PD-L1 is encoded by the nucleic acid sequence as found in SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 14.

5. The use according to any one of claims 1 to 4, wherein the DNA molecule further comprises the kanamycin antibiotic resistance gene, the pMB1 ori and a CMV promoter.

6. The use according to any one of claims 1 to 5 for cancer immunotherapy.

7. The use according to any one of claims 1 to 6, wherein the treatment of cancer further comprises chemotherapy, radiotherapy or biological cancer therapy.

8. The use according to claim 7, wherein the biological cancer therapy comprises administration of at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen and/or a tumor stroma antigen, wherein said at least one further attenuated strain of Salmonella is Salmonella typhi Ty21a comprising a further eukaryotic expression cassette.

9. The use according to claim 8, wherein said tumor antigen encoded by said at least one further DNA vaccine is selected from the group consisting of Wilms' Tumor Protein (WT1), Mesothelin (MSLN), CEA, CMV pp65 and/or wherein said tumor stroma antigen encoded by said at least one further DNA vaccine is VEGFR-2 or human fibroblast activation protein (FAP).

10. The use according to claim 9, wherein said tumor antigen encoded by said at least one further DNA vaccine is selected from the group consisting of Wilms' Tumor Protein (WT1) having the amino acid sequence as found in SEQ ID NO 6 and a protein that shares at least about 80% sequence identity therewith, Mesothelin (MSLN) having the amino acid sequence as found in SEQ ID NO 7 and a protein that shares at least about 80% sequence identity therewith, CEA having the amino acid sequence as found in SEQ ID NO 8 and a protein that shares at least about 80% sequence identity therewith, CMV pp65 having the amino acid sequence as found in SEQ ID NO 9 and a protein that shares at least about 80% sequence identity therewith, CMV pp65 having the amino acid sequence as found in SEQ ID NO 10 and a protein that shares at least about 80% sequence identity therewith, and CMV pp65 having the amino acid sequence as found in SEQ ID NO 11 and a protein that shares at least about 80% sequence identity therewith, and wherein said tumor stroma antigen encoded by said at least one further DNA vaccine is selected from the group consisting of VEGFR-2 having the amino acid sequence as found in SEQ ID

NO 12 and a protein that shares at least about 80% sequence identity therewith and human fibroblast activation protein (FAP).

11. The use according to any one of claims 1 to 10, wherein the attenuated strain of Salmonella is to be administered orally.

12. The use according to any one of claims 1 to 11, wherein the cancer is selected from lymphoma, leukemia, myeloma, lung cancer, in particular non-small cell lung cancer (NSCLC), melanoma, renal cell cancer, ovarian cancer, glioblastoma, merkel cell carcinoma, bladder cancer, head and neck cancer, colorectal cancer, esophagial cancer, cervical cancer, gastric cancer, hepatocellular cancer, prostate cancer, breast cancer, pancreatic cancer, and thyroid cancer**.**

13. The use according to any one of claims 1 to 12, wherein the single dose of the attenuated strain of Salmonella comprises from about 10^5 to about 10^{11}, particularly from about 10^6 to about 10^{10}, more particularly from about 10^6 to about 10^9, more particularly from about 10^6 to about 10^8, most particularly from about 10^6 to about 10^7 colony forming units (CFU).

14. The use according to any one of claims 6 to 13, wherein it is for use in individualized cancer immunotherapy comprising the step of assessing the PD-L1 expression pattern and/or the pre-immune response against PD-L1 of a patient.